Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial - Li, Pan; Gu, Ying; Yang, Yawei; Chen, Lizhi; Liu, Junmei; Gao, Lihong; Qin, Yongwen; Cai, Quancai; Zhao, Xianxian; Wang, Zhuo; Ma, Liping (Scientific reports, 2016)
Keywords: 631/154/109/1940; 631/154/436/108; 631/154/436/1729; 631/154/436/2388; Adenosine - administration & dosage; Adenosine - analogs & derivatives; Adenosine - pharmacokinetics; Adult; Anticoagulants; Bleeding; Blood platelets; Cardiovascular disease; China; Clinical trials; Clopidogrel; Dose-Response Relationship, Drug; Drug dosages; Drug therapy; Electron tubes; Female; Healthy Volunteers; Hospitals; Humanities and Social Sciences; Humans; Male; multidisciplinary; Pharmacokinetics; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - pharmacokinetics; Receptors, Purinergic P2Y12 - metabolism; Science; Ticagrelor; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Young Adult